- Cognetivity Neurosciences (CSE:CGN) has announced a collaboration with UC Health for early detection of cognitive impairment
- The company will provide UC Health’s UC Gardner Neuroscience Institute with access to its AI-powered CognICA cognitive assessment tool
- UC Health will use CognICA to screen patients at risk for cognitive impairment, including seniors and those with cancer, and neurosurgery conditions
- Shares of Cognetivity Neurosciences are unchanged at C$0.13
Cognetivity Neurosciences (CSE:CGN) and UC Health are collaborating on the early detection of cognitive impairment.
In a news release, the Vancouver-based AI healthtech company said its collaboration with UC Health will take place across clinical settings in the United States.
The company will also provide UC Health’s UC Gardner Neuroscience Institute with access to its AI-powered CogniAI cognitive assessment tool, which will evaluate patients’ brain health at primary and secondary care.
“This collaboration is a step forward in our mission to provide routine cognitive screening for all populations at risk of impairment, enabling earlier detection and intervention, leading to better outcomes for patients, allowing them to lead fuller lives,” Mazen Sobh, vice president of commercial development at Cognetivity Neurosciences, said in a statement. “Working with UC Health is a big step forward for us in accessing and developing the U.S. market where there is a huge opportunity in bringing the best in AI-driven technology to the world’s most advanced healthcare market.”
CogniAI is a tool that can be used to assess cognitive function in patients of all ages and backgrounds, at home and in a clinic.
UC Health will use CognICA to screen patients at risk for cognitive impairment, including seniors and those with cancer, and neurosurgery conditions.
Backed by the academic strength of the University of Cincinnati, one of the top 25 public research universities in the U.S., UC Health brings together the region’s top clinicians and researchers to provide world-class care to the Cincinnati community and beyond.
Cognetivity Neurosciences is a technology company that has developed a cognitive testing platform for use in medical, commercial, and consumer environments.
Shares of Cognetivity Neurosciences are unchanged at C$0.13.
Join the discussion: Find out what everybody’s saying about this stock on the Cognetivity Neursciences Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.